http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
CMP cross-correlation analysis of multi-channel surface-wave data
Hayashi Koichi,Suzuki Haruhiko Korean Society of Earth and Exploration Geophysici 2004 지구물리와 물리탐사 Vol.7 No.1
In this paper, we demonstrate that Common Mid-Point (CMP) cross-correlation gathers of multi-channel and multi-shot surface waves give accurate phase-velocity curves, and enable us to reconstruct two-dimensional (2D) velocity structures with high resolution. Data acquisition for CMP cross-correlation analysis is similar to acquisition for a 2D seismic reflection survey. Data processing seems similar to Common Depth-Point (CDP) analysis of 2D seismic reflection survey data, but differs in that the cross-correlation of the original waveform is calculated before making CMP gathers. Data processing in CMP cross-correlation analysis consists of the following four steps: First, cross-correlations are calculated for every pair of traces in each shot gather. Second, correlation traces having a common mid-point are gathered, and those traces that have equal spacing are stacked in the time domain. The resultant cross-correlation gathers resemble shot gathers and are referred to as CMP cross-correlation gathers. Third, a multi-channel analysis is applied to the CMP cross-correlation gathers for calculating phase velocities of surface waves. Finally, a 2D S-wave velocity profile is reconstructed through non-linear least squares inversion. Analyses of waveform data from numerical modelling and field observations indicate that the new method could greatly improve the accuracy and resolution of subsurface S-velocity structure, compared with conventional surface-wave methods.
Fabrication of Nanocomposite Powders by Sonochemical Method
Hayashi, Yamato,Sekino, Tohru,Niihara, Koichi The Korean Powder Metallurgy Institute 2001 한국분말재료학회지 (KPMI) Vol.8 No.3
Nano particles have recently been a major research interest, motivated by their unusual physical and chemical properties. Such particles can be synthesized using physical and chemical methods. The physical methods need expensive installation like vacuum induction furnace, whereas in chemical methods the process in generally very simple and low cost. In this study, simple and new fabrication process by using ultrasound was investigated to prepare the nano-sized metal particles on various powders at room temperature.
Tsuruta, Daisuke,Hayashi, Akihide,Kobayashi, Hiromi,Nakagawa, Koichi,Furukawa, Masayoshi,Ishii, Masamitsu S. Karger AG 2005 Dermatology Vol.210 No.4
<P>We describe 4 cases of pseudocyst of the scalp, which still is only being described in the Japanese literature. The tumor is characterized as follows: localized between the top and the forehead area of the scalp, it first appears as a solitary reddish, painful small nodule or papule; it then gradually increases in size, protruding into a dome-shaped mass, and becomes associated with alopecia limited to the lesion area. This report describes typical cases of pseudocyst of the scalp, reviews the reported Japanese cases and introduces this tumor to western dermatology.</P><P>Copyright © 2005 S. Karger AG, Basel</P>
Murakami, Haruyasu,Nokihara, Hiroshi,Hayashi, Hidetoshi,Seto, Takashi,Park, Keunchil,Azuma, Koichi,Tsai, Chun‐,Ming,Yang, James Chih‐,Hsin,Nishio, Makoto,Kim, Sang‐,We,Kiura, Katsuyu John Wiley and Sons Inc. 2018 CANCER SCIENCE Vol.109 No.9
<P>Epidermal growth factor receptor (EGFR)‐activating mutations confer sensitivity to tyrosine kinase inhibitor (TKI) treatment for non‐small‐cell lung cancer (NSCLC). ASP8273 is a highly specific, irreversible, once‐daily, oral, EGFR TKI that inhibits both activating and resistance mutations. This ASP8273 dose‐escalation/dose‐expansion study (NCT02192697) was undertaken in two phases. In phase I, Japanese patients (aged ≥20 years) with NSCLC previously treated with ≥1 EGFR TKI received escalating ASP8273 doses (25‐600 mg) to assess safety/tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended phase II dose (RP2D) by the Bayesian Continual Reassessment Method. In phase II, adult patients with T790M‐positive NSCLC in Japan, Korea, and Taiwan received ASP8273 at RP2D to further assess safety/tolerability and determine antitumor activity, which was evaluated according to Simon's two‐stage design (threshold response = 30%, expected response = 50%, α = 0.05, β = 0.1). Overall, 121 (n = 45 [33W/12M] phase I, n = 76 [48W/28M]) phase 2) patients received ≥1 dose of ASP8273. In phase I, RP2D and MTD were established as 300 and 400 mg, respectively. As 27 of the 63 patients treated with ASP8273 300 mg achieved a clinical response, ASP8273 was determined to have antitumor activity. The overall response rate at week 24 in all patients was 42% (n = 32/76; 95% confidence interval, 30.9‐54.0). Median duration of progression‐free survival was 8.1 months (95% confidence interval, 5.6, upper bound not reached). The most commonly reported treatment‐related adverse event in phase II was diarrhea (57%, n = 43/76). ASP8273 300 mg was generally well tolerated and showed antitumor activity in Asian patients with both EGFR‐activating and T790M mutations.</P>